Literature DB >> 2050174

Sublingual captopril--a pharmacokinetic and pharmacodynamic evaluation.

T A al-Furaih1, J C McElnay, J S Elborn, R Rusk, M G Scott, J McMahon, D P Nicholls.   

Abstract

In this study we compared the pharmacokinetics and pharmacodynamics of captopril after sublingual and peroral administration. Single 25 mg doses of captopril were administered sublingually and perorally on two different occasions in a randomised cross-over fashion to eight healthy volunteers aged 22-35 years. The kinetics of unchanged captopril, plasma renin activity (PRA). BP and heart rate were studied over three hours after both peroral and sublingual administration of captopril. Mean pharmacokinetic parameters for unchanged captopril after sublingual administration were: Cmax, 234 ng.ml-1; tmax, 45 min; AUC (0-3 h), 15.1 micrograms.ml-1.min. Mean pharmacokinetic parameters for unchanged captopril after peroral administration were; Cmax, 228 ng.ml-1; tmax, 75 min; AUC (0-3 h), 17.0 micrograms.ml-1.min.tmax was significantly shorter when captopril was administered sublingually; all other pharmacokinetic parameters were equivalent. The plasma captopril concentrations achieved post drug administration led to increases in PRA and reductions in BP.tmax for PRA was 86 min for sublingual captopril and 113 min for perorally administered drug. Peak PRA values were, however, not significantly different. BP, as expected, was not reduced dramatically in these healthy volunteer subjects, however, in systolic BP vs time profiles, BP was significantly lower after volunteers received sublingual captopril. Heart rate increased slightly after captopril administration; there were no differences between the two routes of administration. Administration of captopril sublingually, therefore led to a more rapid attainment of plasma captopril concentrations and had a more rapid onset of pharmacological effect when compared with peroral administration.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2050174     DOI: 10.1007/bf00265850

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  Pharmacokinetics of captopril and its effects on blood pressure during acute and chronic administration and in relation to food intake.

Authors:  K P Ohman; B Kågedal; R Larsson; B E Karlberg
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

2.  Effect of a single dose of sublingual captopril in hypertensive patients.

Authors:  J H Hauger-Klevene
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

3.  [Hypertensive crisis: comparative study of oral captopril, sublingual captopril and sublingual nifedipine].

Authors:  A Martínez Amenós; J Carratalà; X Pintó; M Santaló; C Tamayo; M Pujol
Journal:  Med Clin (Barc)       Date:  1987-06-06       Impact factor: 1.725

4.  Simplified determination of captopril in plasma by high-performance liquid chromatography.

Authors:  C M Pereira; Y K Tam; R L Collins-Nakai; P Ng
Journal:  J Chromatogr       Date:  1988-03-04

5.  Captopril in patients with ileus.

Authors:  J J McMurray; A D Struthers
Journal:  Lancet       Date:  1988-02-27       Impact factor: 79.321

6.  Sublingual captopril in hypertensive crisis.

Authors:  W Tschollar; G G Belz
Journal:  Lancet       Date:  1985-07-06       Impact factor: 79.321

7.  Comparison of sublingual captopril and nifedipine.

Authors:  J H Hauger-Klevene
Journal:  Lancet       Date:  1986-01-25       Impact factor: 79.321

8.  Comparison of sublingual and oral captopril in hypertension.

Authors:  P Dessì-Fulgheri; F Bandiera; S Rubattu; F Cocco; P Madeddu; M Oppes; G C Tonolo; N Glorioso; A Rappelli
Journal:  Clin Exp Hypertens A       Date:  1987

Review 9.  Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases.

Authors:  K L Duchin; D N McKinstry; A I Cohen; B H Migdalof
Journal:  Clin Pharmacokinet       Date:  1988-04       Impact factor: 6.447

  9 in total
  5 in total

Review 1.  Clinical pharmacokinetics of drug administered buccally and sublingually.

Authors:  J G Motwani; B J Lipworth
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

2.  The effect of pH on the buccal and sublingual absorption of captopril.

Authors:  J C McElnay; T A al-Furaih; C M Hughes; M G Scott; J S Elborn; D P Nicholls
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

3.  A pharmacokinetic and pharmacodynamic evaluation of buffered sublingual captopril in patients with congestive heart failure.

Authors:  J C McElnay; T A al-Furaih; C M Hughes; M G Scott; D P Nicholls
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

4.  The effect of sublingual captopril versus intravenous enalaprilat on angiotensin II plasma levels.

Authors:  Hein A van Onzenoort; Michiel Bussink; Paul P Menheere; Walther N van Mook; Paul-Hugo M van der Kuy
Journal:  Pharm World Sci       Date:  2006-09-27

Review 5.  Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications.

Authors:  Hao Zhang; Jie Zhang; James B Streisand
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.